Nuformix PLC NXP002 Orphan Drug Designation Draft Application

RNS Number : 9865S

Nuformix PLC

13 January 2025

 

13 January 2025

 

Nuformix plc

 

("Nuformix" or the "Company")

 

NXP002 Orphan Drug Designation Draft Application

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce that it has submitted a draft application document in advance of a pre-submission meeting with the European Medicines Agency ("EMA") regarding an Orphan Drug Designation ("ODD") for the Company's lead asset NXP002, a potential novel inhaled treatment for Idiopathic Pulmonary Fibrosis ("IPF").  This is the first stage in the process for the Company to potentially secure ODD for NXP002 in IPF.

 

The pre-submission meeting will occur later in January 2025.  The EMA strongly encourages sponsors to request a pre-submission meeting prior to filing an application, the precise timing of which will depend upon feedback received, but could be before the end of January 2025.  Upon submission of the application the Company will make a further announcement and confirm the anticipated timelines associated with the review and the EMA's decision on NXP002's ODD in IPF.

 

The Company is also pleased to confirm that discussions with potential partners to secure an out-licence or option agreement for NXP002 continue to proceed with a number of parties.

 

Enquiries:

 

Nuformix plc
Dr Dan Gooding, Executive Director	Via IFC Advisory
CMC Markets
Douglas Crippen	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities.  Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDBBMJTMTBBBRA